Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Humacyte (HUMA) Non-Current Assets (2024 - 2025)

Humacyte has reported Non-Current Assets over the past 2 years, most recently at $48.6 million for Q4 2025.

  • Quarterly results put Non-Current Assets at $48.6 million for Q4 2025, down 46.04% from a year ago — trailing twelve months through Dec 2025 was $274.6 million (up 2.68% YoY), and the annual figure for FY2025 was $48.6 million, down 46.04%.
  • Non-Current Assets for Q4 2025 was $48.6 million at Humacyte, down from $50.2 million in the prior quarter.
  • Over the last five years, Non-Current Assets for HUMA hit a ceiling of $91.8 million in Q3 2024 and a floor of $42.2 million in Q2 2024.